- Home
- LSBK vs STRO Comparison
LSBK vs STRO Comparison
Compare LSBK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- STRO
- Stock Information
- Founded
- LSBK 1891
- STRO 2003
- Country
- LSBK United States
- STRO United States
- Employees
- LSBK N/A
- STRO N/A
- Industry
- LSBK Savings Institutions
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSBK Finance
- STRO Health Care
- Exchange
- LSBK Nasdaq
- STRO Nasdaq
- Market Cap
- LSBK 90.0M
- STRO 74.3M
- IPO Year
- LSBK 2006
- STRO 2018
- Fundamental
- Price
- LSBK $13.03
- STRO $0.89
- Analyst Decision
- LSBK
- STRO Hold
- Analyst Count
- LSBK 0
- STRO 7
- Target Price
- LSBK N/A
- STRO $1.97
- AVG Volume (30 Days)
- LSBK 28.8K
- STRO 514.4K
- Earning Date
- LSBK 10-22-2025
- STRO 11-12-2025
- Dividend Yield
- LSBK 2.76%
- STRO N/A
- EPS Growth
- LSBK 39.59
- STRO N/A
- EPS
- LSBK 1.05
- STRO N/A
- Revenue
- LSBK $26,488,000.00
- STRO $104,473,000.00
- Revenue This Year
- LSBK N/A
- STRO $65.42
- Revenue Next Year
- LSBK N/A
- STRO N/A
- P/E Ratio
- LSBK $12.48
- STRO N/A
- Revenue Growth
- LSBK 1.75
- STRO N/A
- 52 Week Low
- LSBK $11.50
- STRO $0.52
- 52 Week High
- LSBK $13.48
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- LSBK 55.76
- STRO 48.88
- Support Level
- LSBK $12.96
- STRO $0.85
- Resistance Level
- LSBK $13.26
- STRO $1.01
- Average True Range (ATR)
- LSBK 0.19
- STRO 0.09
- MACD
- LSBK -0.06
- STRO -0.01
- Stochastic Oscillator
- LSBK 28.57
- STRO 12.61
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.